Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 14, 2019

View Archived Issues

Metformin rejuvenates stem cells, restores CNS remyelination

Enrollment begins in first-in-human study of REGN-5459

Libella Gene Therapeutics initiates phase I study of its AAV-hTERT gene therapy

Phase II RESIST study of MAP-4343 begins in patients with drug-resistant depression

Novartis presents data from ASCEND-7 phase II study of ceritinib

ABCC3 as a novel pharmacological target in pancreatic cancer

New insulin receptor partial agonists discovered at Merck & Co.

Emory University discloses CXCR-4 and/or CCR5 antagonists

Well Marker Bio describes new macrophage-stimulating protein receptor inhibitors

[177Lu]PSMA-R2 shows strong antitumor activity in prostate cancer xenograft model

Better late than never for schizophrenia gene targeting

Mitochondrial mutations hamper nuclear DNA repair

Novel phenylpropanoid analogue promotes neurogenesis, ameliorates cognitive impairment in AD models

Evaluating the role of UCK2 as a biomarker for patient selection for RX-3117 treatment

Synblia Therapeutics patents PTPN11 inhibitors

Dual IDO-1/TDO inhibitors presented by CHA Health Systems and CMG Pharmaceutical

RedHill reports full data from phase III MAP US study of RHB-104 in Crohn's disease

FDA approves Reyvow for acute treatment of migraine

RegenxBio presents phase I/IIa interim data on RGX-314 in wet AMD

Eyevensys provides initial data from phase I/II study of EYS-606 for noninfectious uveitis

Auris reports phase Ib interim data on AM-201 for antipsychotic-induced weight gain and somnolence

Kodiak reports phase Ib data on KSI-301 in wet AMD, DME and RVO

[68Ga]FAPI-04 imaging evaluated in studies in cancer patients

ReNeuron announces phase I/IIa data on hRPC stem cell therapy in retinitis pigmentosa

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...